KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to $122.4 million.

  • West Pharmaceutical Services' Net Cash Flow rose 26428.57% to $122.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $136.9 million, marking a year-over-year increase of 13232.59%. This contributed to the annual value of -$347.9 million for FY2024, which is 57162.16% down from last year.
  • According to the latest figures from Q3 2025, West Pharmaceutical Services' Net Cash Flow is $122.4 million, which was up 26428.57% from $87.0 million recorded in Q2 2025.
  • Over the past 5 years, West Pharmaceutical Services' Net Cash Flow peaked at $126.5 million during Q4 2022, and registered a low of -$243.4 million during Q1 2024.
  • For the 5-year period, West Pharmaceutical Services' Net Cash Flow averaged around $1.4 million, with its median value being $33.6 million (2024).
  • In the last 5 years, West Pharmaceutical Services' Net Cash Flow plummeted by 152266.67% in 2024 and then surged by 26428.57% in 2025.
  • West Pharmaceutical Services' Net Cash Flow (Quarter) stood at $77.2 million in 2021, then soared by 63.86% to $126.5 million in 2022, then crashed by 146.8% to -$59.2 million in 2023, then soared by 127.7% to $16.4 million in 2024, then surged by 646.34% to $122.4 million in 2025.
  • Its last three reported values are $122.4 million in Q3 2025, $87.0 million for Q2 2025, and -$88.9 million during Q1 2025.